The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This was published in Share Magazine 11:47 on line.
"Shares in skin analytics company Integumen (SKIN:AIM) surged 18% higher on Thursday to 62.5p following the unveiling of a Covid-19 personalised, real-time breath test.
MICROTOX-BT
Adapting its previously unveiled wastewater test in collaboration with Modern Water (MWG:AIM), Avacta (AVCT:AIM) and Aptamer Group, the group has designed, built and tested a prototype called Microtox-BT, which can analyse the breath and detect the spike protein of SARS-CoV-2 in real-time for those carrying a high viral load.
After extensive internal testing, the University of Aberdeen will initiate further testing followed by a joint-trial of up to 5,000 people in parallel with third parties, with results expected before the end of the year.
The company has also incorporated a 24 hour Digital Health Pass that indicates if someone tests positive or negative for infection. Providing a secure date and time stamp and ‘one second’ QR scanners, the pass would enable personalised go/no go entry into venues such as work, social locations, public transport and airports.
Chief executive Gerry Brandon said, ‘The company believes that to enable the economy to re-open fully, the public are going to have to take the responsibility of testing against this virus, themselves.
‘By providing an instant real-time breath test with a digital reader platform, and combined with appropriately priced products, we can drive a consumer-led duty of care for personal Covid-19 responsibility.’
WASTE WATER DETECTION SYSTEM
Integumen also confirmed it had completed the integration of a real-time Covid-19 detector and alert system into Modern Water’s Microtox water contamination system, called Microtox PD.
The anticipated launch for the product is in early 2021 and will be sold through Modern Water’s global distribution platform of over 3,000 installations."
The company has signed a memorandum of understanding for agreements to be concluded for the supply of commercial quantities of binding agents from Avacta and Aptamer group to be used in the next generation sensors.
Hopefully, this will spread the word and attract more investors . GLA